Navigation Links
Investigational Diabetes Drug May Also Have Future As Treatment for Parkinson's Disease

KALAMAZOO, Mich., Sept. 19, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the presentation of new data showing an investigational drug being studied to treat diabetes, MSDC-0160, had a protective effect  on nerve cells in the brain that control movement, balance and walking.  These results in laboratory and animal models of Parkinson's disease suggest MSDC-0160 may have the potential to modify the course of Parkinson's disease. The Company is preparing for the start of clinical trials, which could begin in late 2014.

These results were generated in collaboration with Patrik Brundin, MD, PhD, Head of the Laboratory of Translational Parkinson's Disease Research and Director of the Center for Neurodegenerative Science at the Van Andel Institute (VAI). The data were presented by post-doctoral fellow Anamitra Ghosh at the "Grand Challenges in Parkinson's Disease" symposium, which is being convened September 18 – 19 at VAI (Grand Rapids, MI).

First in Class
MSDC-0160 is the first in a new class of insulin sensitizers called mTOT Modulators™, which appear to exert their therapeutic effects through a new drug target located in the inner mitochondrial membrane. MSDC-0160 has been shown to be well-tolerated and no significant safety issues were noted in studies in patients with type 2 diabetes or elderly patients with dementia due to Alzheimer's disease. In a Phase 2b clinical trial in 258 patients with type 2 diabetes, MSDC-0160 was shown to lower hemoglobin A1c significantly without the side effect profile of currently marketed insulin sensitizers, which are PPARg agonists. In a recently completed Phase 2a trial in 29 patients with dementia due to Alzheimer's disease (NCT01374438), MSDC-0160 was shown to maintain or increase glucose metabolism in the brain, as measured by FDG-PET imaging, in predefined regions of interest in the brain associated with cognitive decline.

Mitochondria and Parkinson's Disease
Parkinson's disease is a chronic, degenerative neurological disorder that affects an estimated one million people in the United States, and more than five million worldwide. Impaired mitochondrial function has been implicated in the development of Parkinson's disease. Mitochondria are the "power plants" of the cell, generating energy needed for cell activity. Therapies that improve mitochondrial function may have the potential to slow the progression of the disease.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company ( is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

About Van Andel Institute
Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. This is accomplished through the work of over 200 researchers in more than 20 on-site laboratories and in collaborative partnerships that span the globe. Find out more about Van Andel Institute or donate by visiting

About Patrik Brundin, MD, PhD
Patrik Brundin, M.D., Ph.D. Brundin has more than 30 years of experience with neurodegenerative diseases, Parkinson's disease pathogenesis, and therapeutic neural grafting into people with Parkinson's disease. He is one of the top cited researchers in the field of neuroscience with around 300 publications on Parkinson's disease and related topics. In addition to managing laboratories at VAI and at Lund University, Sweden, he is the co-editor in chief of the Journal of Parkinson's Disease and has coordinated multiple international research programs.  

SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
2. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
3. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
4. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
5. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
8. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
9. Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
10. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
11. Research Report on Chinas Diabetes Drug Market, 2013-2017
Post Your Comments:
(Date:11/24/2015)... INCLINE VILLAGE, Nev. , Nov. 24, 2015  PDL ... John P. McLaughlin , the company,s president and chief ... Piper Jaffray Healthcare Conference next week in New ... and will occur on Tuesday, December 1, 2015 at 9:30 ... and Presentations." Please connect to the website at least 15 ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two ... in 2005. This is something that many doctors, scientists, and ... One questions remains: with fewer PSA tests being done, will ... Dr. David Samadi, "Despite the efforts ... disease remains the second leading cancer cause of death in ...
(Date:11/23/2015)... HONG KONG, Nov. 23, 2015 China Cord ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2016 ended September 30, 2015. --> ... Highlights , Revenues for the second quarter of ...
(Date:11/23/2015)... The royalty-free a greement a llows ... 112 low- and m iddle-i ncome ... --> The Medicines Patent Pool (MPP) today announced its ... with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that ... virus.  The royalty-free licence will enable generic manufacture of daclatasvir ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
Breaking Biology News(10 mins):